6.
Attard G, Swennenhuis J, Olmos D, Reid A, Vickers E, AHern R
. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res. 2009; 69(7):2912-8.
DOI: 10.1158/0008-5472.CAN-08-3667.
View
7.
Bober P, Alexovic M, Tomkova Z, Kilik R, Sabo J
. RHOA and mDia1 Promotes Apoptosis of Breast Cancer Cells Via a High Dose of Doxorubicin Treatment. Open Life Sci. 2021; 14:619-627.
PMC: 7874778.
DOI: 10.1515/biol-2019-0070.
View
8.
Lukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanislawek A
. Breast Cancer-Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies-An Updated Review. Cancers (Basel). 2021; 13(17).
PMC: 8428369.
DOI: 10.3390/cancers13174287.
View
9.
Deng Z, Wu S, Wang Y, Shi D
. Circulating tumor cell isolation for cancer diagnosis and prognosis. EBioMedicine. 2022; 83:104237.
PMC: 9440384.
DOI: 10.1016/j.ebiom.2022.104237.
View
10.
Park M, Kim D, Ko S, Kim A, Mo K, Yoon H
. Breast Cancer Metastasis: Mechanisms and Therapeutic Implications. Int J Mol Sci. 2022; 23(12).
PMC: 9224686.
DOI: 10.3390/ijms23126806.
View
11.
Debnath P, Huirem R, Dutta P, Palchaudhuri S
. Epithelial-mesenchymal transition and its transcription factors. Biosci Rep. 2021; 42(1).
PMC: 8703024.
DOI: 10.1042/BSR20211754.
View
12.
Cristofanilli M, Budd G, Ellis M, Stopeck A, Matera J, Miller M
. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8):781-91.
DOI: 10.1056/NEJMoa040766.
View
13.
Zhao L, Wu X, Li T, Luo J, Dong D
. ctcRbase: the gene expression database of circulating tumor cells and microemboli. Database (Oxford). 2020; 2020.
PMC: 7158883.
DOI: 10.1093/database/baaa020.
View
14.
Zhang H, Kong Q, Wang J, Jiang Y, Hua H
. Complex roles of cAMP-PKA-CREB signaling in cancer. Exp Hematol Oncol. 2020; 9(1):32.
PMC: 7684908.
DOI: 10.1186/s40164-020-00191-1.
View
15.
Mittal V
. Epithelial Mesenchymal Transition in Tumor Metastasis. Annu Rev Pathol. 2018; 13:395-412.
DOI: 10.1146/annurev-pathol-020117-043854.
View
16.
Lara O, Tong X, Zborowski M, Chalmers J
. Enrichment of rare cancer cells through depletion of normal cells using density and flow-through, immunomagnetic cell separation. Exp Hematol. 2004; 32(10):891-904.
DOI: 10.1016/j.exphem.2004.07.007.
View
17.
Alsuliman A, Colak D, Al-Harazi O, Fitwi H, Tulbah A, Al-Tweigeri T
. Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells. Mol Cancer. 2015; 14:149.
PMC: 4527106.
DOI: 10.1186/s12943-015-0421-2.
View
18.
Guo R, Liu T, Shasaltaneh M, Wang X, Imani S, Wen Q
. Targeting Adenylate Cyclase Family: New Concept of Targeted Cancer Therapy. Front Oncol. 2022; 12:829212.
PMC: 9271773.
DOI: 10.3389/fonc.2022.829212.
View
19.
Czubak-Prowizor K, Babinska A, Swiatkowska M
. The F11 Receptor (F11R)/Junctional Adhesion Molecule-A (JAM-A) (F11R/JAM-A) in cancer progression. Mol Cell Biochem. 2021; 477(1):79-98.
PMC: 8755661.
DOI: 10.1007/s11010-021-04259-2.
View
20.
Wang C, Mu Z, Ye Z, Zhang Z, Abu-Khalaf M, Silver D
. Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors. Breast Cancer Res Treat. 2020; 181(3):679-689.
PMC: 7299127.
DOI: 10.1007/s10549-020-05662-x.
View